Introduction {#Sec1}
============

Reports are emerging from China and Italy and increasingly from several countries of neurological symptoms associated with SARS-CoV-2, which may be worsening clinical pictures, respiratory outcomes and mortality rates in patients with COVID-19. While most coronaviruses cause mild respiratory illness, it is well known that many beta-coronaviruses have nervous system involvement \[[@CR1]\]. Sharing similar genetic traits with MERS and SARS \[[@CR2], [@CR3]\] as well as a common host cell entry receptor with SARS \[[@CR4]\], SARS-CoV-2 may also demonstrate neurotropism via possible invasion through the cribriform plate, olfactory nerve, thalamus and brainstem resulting in suppression of central cardiorespiratory drive \[[@CR5]\]. Reports from China describe neurological symptoms in COVID-19 patients with one retrospective case series from Wuhan, China showing 78 of 214 patients (36%) with neurological manifestations \[[@CR6]--[@CR8]\]. Observations from Italy have confirmed Chinese data noting a high number of patients with hyposmia, anosmia and varying patterns of possibly centrally mediated symptoms including respiratory manifestations. In the evolving pandemic, healthcare professionals, therefore, need to recognize and address neurological consequences. We summarized the available knowledge to guide further research, clinical surveillance and management protocols.

Methods {#Sec2}
=======

We searched papers published in English by 5 April 2020 using PubMed. Search terms relating to COVID-19 (including COVID\*, novel coronavirus, nCoV\*, \*CoV-2, or \*CoV2) in titles and abstracts were crossed with terms relating to neurological symptoms or neurotropism including (neurolog\*, nervous, dizz\*, delirium, encephal\*, cereb\*, headache, hyposmia, \*geusia, hypopsia, myalgia, neurotrop\*, or neuroinv\*) in full texts. The search resulted in 198 papers, with 154 unique results retrieved, of which 122 were excluded on title/abstract screen and four were excluded on full text screen. Exclusion was based on topic, outcomes covered, and full text unavailability. 29 papers related to neurological manifestations associated with COVID-19 were examined.

Results {#Sec3}
=======

Evidence of neurological symptoms of COVID-19 {#Sec4}
---------------------------------------------

Respiratory distress is the most distinctive symptom (55%) reported in COVID-19 patients \[7\]. Reported neurological findings fall into three categories: central (headache \[[@CR6], [@CR7]\], dizziness \[[@CR6]\], impaired consciousness, acute cerebrovascular disease, ataxia and seizures), peripheral (hypogeusia, hyposmia) and musculoskeletal \[[@CR8]\]. Mao et al. reported that 6 of 214 patients had either ischemic or haemorrhagic strokes, although it was not reported whether the strokes occurred before or after SARS-CoV-2 infection. Approximately 5% reported hypogeusia (5.6%) and/or hyposmia (5.1%) \[[@CR8]\]. Additionally, a clinical picture reminiscent of a central hypoventilation syndrome ("Ondine's curse") was reported from a COVID-19 survivor in Wuhan \[[@CR5]\]. There have been increasing reports of delirium in COVID-19 patients, and delirium may also be associated with more severe disease. A recent retrospective case series from China found that 22% of people who died from COVID-19 experienced delirium compared with 1% of people who recovered \[[@CR9]\]. There has also been a case report of altered mental status in a COVID-19 patient with encephalopathy on EEG \[[@CR10]\] and acute haemorrhagic necrotizing encephalopathy, the latter of which was thought to be due to cytokine storm \[[@CR11]\]. Myalgia and muscle injury were reported in 10.7% of the cases in Wuhan \[[@CR8]\] and rhabdomyolysis has been reported in another case from Wuhan \[[@CR12]\].

Neurological manifestations have also been observed first-hand in Italy's Brescia province which documented 9340 COVID-19 patients as of April 5, 2020 (personal observations of authors AP ML).Many patients experienced hyposmia or anosmia, dysgeusia, dysarthria and either allodynia or acroparesthesias. An atypical onset has been observed in few patients characterized by a delirious presentation that occurs prior to the onset of any respiratory syndromes. Within a cohort of 2660 hospitalized COVID-19 patients, 6 patients presented with encephalitis as the first and only symptom, 2 of whom subsequently died. Four patients presented with new onset seizures with no fever. These symptoms were then followed by the respiratory syndrome. There is evidence that many patients displayed varying patterns of respiratory manifestations. One such presentation consists of a sudden onset of respiratory failure in contrast to severe acute pulmonary failure. There also seems to be increase in number of both ischemic stroke and haemorrhagic stroke compared to historical series. Finally, more recently a case report has been published about the onset of Guillaine Barrè syndrome (GBS) during SARS-CoV-2, suggesting a pattern of a parainfectious profile, instead of the classic postinfectious profile \[[@CR13]\].

Discussion {#Sec5}
==========

Neurological manifestations or NeuroCOVID are part of the COVID-19 clinical picture, but questions remain regarding the frequency and severity of CNS symptoms, the mechanism of action underlying neurological symptoms, and the relationship of symptoms with the course and severity of COVID-19. Further clinical, epidemiological, and basic science research is urgently needed to understand and address neurological sequalae of COVID-19. We identified three key priority areas for NeuroCOVID:

First, are patients with COVID-19 in other countries experiencing neurologic symptoms and do these symptoms affect the severity and course of the illness, specifically are they associated with increased respiratory failure or death? Documentation of neuropsychiatric comorbidities and drug treatment regimens is essential to aid ongoing discussions of drug--drug interactions and pharmacodynamic effects. Vaccine research discoveries need to be implemented while keeping in mind possible adverse events as shown by our experiences with the swine flu \[[@CR14]\].

Second, what is the mechanism of action causing the neurological symptoms seen in patients with COVID-19? It is possible that SARS-CoV-2 causes neurological sequelae via inflammation, as elevated inflammatory biomarkers in patients with COVID-19 have been noted. Pro-inflammatory cytokine release is known to cause severe pulmonary damage in COVID-19, termed "cytokine storm", and likely affects the CNS as well. Indirect CNS damage, through cytokine storm, can cause high mortality rates, encephalopathy, and posterior reversible encephalopathy (PRES). In acute infections, cytokine release can also result in strokes, a number of which have been reported in SARS post infection \[[@CR17]\]. MR imaging might provide further information to elucidate the role of brainstem respiratory centres in COVID-19 patients.

Third, is SARS-CoV-2 a neurotropic virus? While we know that other coronaviruses demonstrate neurotropism, it is unknown how much of this knowledge is relevant for SARS-CoV-2. Li et al. postulate that SARS-CoV-2 neuroinvasion via the olfactory nerves is partially responsible for respiratory failure \[[@CR5]\]. Is hyposmia or anosmia part of a prodrome of symptoms in COVID-19? Further research is needed in this area to further understand why steroids may be counterproductive in management of COVID-19 \[[@CR18]\]. This signifies the importance of carrying out research into therapeutic options systematically with shared protocols and critical comparison of results.

Many patients present dysgeusia, dysphagia, dysarthria (personal observation AP) indicating a possible vagal involvement which could also indicate the possibility for diaphragmatic paresis and tachycardia thus potential bulbar infections. We know that SARS-CoV-1 enters cells through the ACE2 receptor mainly in renal, cardiovascular and gastrointestinal systems \[[@CR19]--[@CR22]\]. In mice, infected hippocampal cells were isolated in the CNS several days post-infection indicating that SARS-CoV-1 has the capability to spread to the CNS after clearance by the lungs \[[@CR23]\]. In humans, SARS-CoV-1 has been found in the CSF \[[@CR24]\] and in neurons on autopsy \[[@CR25], [@CR26]\]. Another coronavirus (swine hemagglutinating encephalomyelitis virus) travels via peripheral nerves to the brainstem via trigeminal and vagal sensory nuclei \[[@CR27]--[@CR29]\]. HCoV OC43 (a coronavirus responsible for the common cold) infects human microglia leading to persistent infection and has been found in the CSF and brain tissue of patients \[[@CR30]--[@CR32]\]. In mice, it travels to the CNS from the olfactory bulbs and, importantly, is blocked by destroying olfactory sensory neurons \[[@CR33]\]. This potential mechanism becomes crucially important clinically when considering that wearing masks could likely be the most effective prevention against viral entry into the CNS.

Finally, prospective cohort studies are needed to understand the long-term impacts of COVID-19 on neurological functions. It is currently unknown if people who have recovered from severe COVID-19 suffer any lasting neurological sequalae. It is certainly true and well known that several patients discharged from ICU, thus also several COVID 19 patients, suffer of chronic illness myopathy or neuropathy or both which might worsen the clinical outcomes. Concomitant risk factors or determinants (e.g. demographic factors, comorbidities, or available biomarkers) that may predispose a person with COVID-19 to neurological manifestations should be identified.

We are aware that this review has limitations including that it was limited to articles published in English and that there is a tremendous growth in the volume of published literature on COVID-19, so that findings and recommendations are constantly evolving as new evidence arises and thus other relevant information and data could be lacking. Answers to all the above questions, however, require close coordination and open-data sharing between hospitals, academic institutions and fast establishment of harmonised research priorities and research consortia to face the NeuroCOVID-19 complications.
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